The futures have picked up a bit after the PPI report. The QQQQ is just below yesterday’s high. Taking out that level should put the bears on the defensive.
Potential swing trades:
See one of the recent ‘Chart Reading‘ posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
NBIX -44.2% (receives Non-Approvable Letter for indiplon capsules and Non-Approvable for indiplon tablets for the treatment of insomnia); DOVE -28.1% (NBIX news); COGN -12.1% (downgraded at Piper Jaffray); REDF -11.9% (reports earnings); DISH -4.2% (downgraded at Morgan Stanley); OXY -2.1% (production agreement cancelled with Ecuador); HD -1.9% (reports Q1 results); DE -1.8% (reports Q1 results).
Gapping Up
NCOG +43.3% (Announces Receipt of ‘Going Private’ Proposal at $27.50 Per Share); CAMT +17.7% (reports Q1 results); SEPR +14.2% (NBIX); FOSL +9.3% (reports Q1 results); HTHM +4.9% (CEO appears on CNBC to discuss Prometa); HSII +4.5% (Merrill upgrades to Buy); KOOL +4.5% (initiated with a Buy at Jefferies); GIGM +4.5% (sells A.D.S.L. Business; one-time gain expected); XMSR +4.3% (Upgraded at Morgan Stanley); JBX +3.8% (reports Q2 results); CELG +3.8% (subsidiary announces intellectual property state strengthened by patent wins); RIO +2.9% (sets deal for an increase in iron-ore Prices); SNDK +2.7% (Merril upgrades to Buy); SOHU +2.5% (Upgraded at Susquehanna); ADBE +2.5% (Upgraded at Baird); AZR +2.1% (determines that revised offer from Columbia Entertainment is superior); RIMM +1.5% (RIMM Capital Markets Day); BSX +1.6% (MELODIE clinical trial reports excellent safety and efficacy results for Express Vascular LD stent); GME +1.2% (positive game data); LM +1.2% (Merrill upgrades to Buy); FD +1.1% (raises Q2 and Y06 earnings guidance to include tax settlement).
Disclaimer & How I use this list
